Sesen Bio (SESN) Stock Analysis

What Sesen Bio does

Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Key metrics

ETFs linked to SESN

Broad-market and Healthcare sector ETFs an investor holding Sesen Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SESN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Sesen Bio?

Sesen Bio trades under the ticker SESN on NASDAQ.

Which exchange is SESN listed on?

SESN is listed on NASDAQ.

What sector does Sesen Bio operate in?

Sesen Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SESN in a portfolio?

PortView shows SESN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.